10-Q: Bolt Projects Reports Q3 Loss, Revenue Up, Nasdaq Threat Looms

Bolt Projects Holdings, Inc. reported a reduced net loss and significantly increased revenue for Q3 2025, but faces substantial doubt about its going concern ability and a Nasdaq delisting threat.

Summary

• Net loss for the nine months ended September 30, 2025, significantly improved to $18.0 million from $59.1 million in the prior year.
• Revenue for the nine months ended September 30, 2025, surged to $1.843 million, a 2,204% increase from $0.080 million in the same period last year.
• Gross income turned positive to $0.119 million for the nine months ended September 30, 2025, compared to a gross loss of $0.075 million in the prior year.
• Operating expenses decreased by 58% to $14.7 million for the nine months ended September 30, 2025, from $35.0 million in the prior year.
• Cash used in operating activities decreased substantially to $2.6 million for the nine months ended September 30, 2025, from $13.4 million in the prior year.
• The company has an accumulated deficit of $479.8 million and negative net working capital of $3.3 million as of September 30, 2025.
• Nasdaq granted an extension until December 31, 2025, to regain compliance with listing standards, specifically the minimum equity standard, and will phase down to the Nasdaq Capital Market.
• The company completed several financing activities, including a $0.5 million common stock sale to Triton, a $1.7 million vendor payable settlement via stock issuance (Seneca Transaction), and a $4.25 million PIPE transaction.
• An equity line of credit facility for up to $20.0 million with Ascent Partners Fund LLC was established in September 2025, with $1.8 million utilized in October 2025.

Sentiment

Score: 3

Explanation: Despite substantial improvements in revenue and a reduced net loss, the company explicitly states "substantial doubt" about its ability to continue as a going concern. Ongoing Nasdaq delisting threats and identified material weaknesses in internal controls overshadow the operational improvements and recent capital raises, indicating a highly precarious financial position.

Positives

• Significant revenue growth of 2,204% to $1.843 million for the nine months ended September 30, 2025, driven by increased sales of Vegan Silk Technology Platform products.
• Improved gross income, turning positive to $0.119 million for the nine months ended September 30, 2025, from a gross loss of $0.075 million in the prior year, due to manufacturing efficiencies and pricing discipline.
• Substantial reduction in net loss to $18.0 million for the nine months ended September 30, 2025, from $59.1 million in the prior year.
• Operating expenses decreased by 58% to $14.7 million for the nine months ended September 30, 2025, reflecting efficient cost management.
• Cash used in operating activities significantly reduced to $2.6 million for the nine months ended September 30, 2025, from $13.4 million in the prior year.
• Successful capital raising efforts, including a $4.25 million PIPE transaction and establishing a $20.0 million equity line of credit.
• Regained compliance with Nasdaq's minimum bid price requirement after a 1-for-20 reverse stock split.

Negatives

• Substantial doubt about the ability to continue as a going concern for the next twelve months due to historical losses, negative cash flows, and insufficient cash and cash equivalents ($4.7 million as of September 30, 2025).
• Accumulated deficit increased to $479.8 million as of September 30, 2025, from $461.8 million at December 31, 2024.
• Negative net working capital of $3.3 million as of September 30, 2025.
• Received a Nasdaq delisting notice on August 12, 2025, for failing to meet minimum Market Value of Listed Securities ($50 million) and Market Value of Publicly Held Shares ($15 million) requirements.
• Identified material weaknesses in internal control over financial reporting, including insufficient technical accounting competency, lack of formal accounting policies, and ineffective IT general controls.
• Reliance on a single manufacturing partner, Laurus Bio, for Vegan Silk Technology products, posing supply chain risk.
• High customer concentration, with two customers accounting for 48% and 36% of Q3 2025 revenue, and one customer for 85% of nine-month 2025 revenue.
• Excise tax payable of $2.925 million as of September 30, 2025, with ongoing interest and penalties due to non-payment.
• Loss on debt extinguishment of $3.053 million for the nine months ended September 30, 2025, related to the Seneca Transaction.

Risks

• History of losses and negative cash flows from operations raise substantial doubt about the company's ability to continue as a going concern.
• Inability to generate sufficient cash to service all debt obligations may force the company to take other actions to satisfy obligations, which may not be successful.
• Failure to meet the continued listing requirements of Nasdaq could result in a delisting of common stock, negatively impacting its price and ability to raise capital.
• Significant future expenses and capital expenditures are expected to execute the business plan, and the company may be unable to adequately control expenses or raise additional capital on favorable terms, if at all.
• Revenue is primarily generated from sales of the Vegan Silk Technology Platform, making the company highly dependent on the success of this product.
• The Vegan Silk Technology Platform has limited product and brand recognition within the beauty and personal care market as a substitute for silicone elastomers.
• The Vegan Silk Technology Platform and future biomaterial product candidates may not achieve market success, potentially preventing the generation of significant revenues.
• Reliance on a single manufacturing partner and facility (Laurus Bio) for production creates a concentration risk, where an interruption could impair the company's ability to produce products.
• A limited number of customers, distributors, and collaboration partners account for a material portion of revenue, and the loss of major ones could harm operating results.
• Certain contracts granting exclusivity rights to customers may limit the company's ability to sell products in certain markets.
• Substantial competition from incumbent materials and other new entrants could lead to failure to gain or loss of market share if the company cannot continue developing innovative products and scale production.
• Material weaknesses in internal control over financial reporting, if not remediated, could lead to inaccurate or untimely financial reporting, adversely affecting investor confidence.
• Inadequate protection of patents and other intellectual property assets could adversely affect the competitive position and reduce product value, with costly litigation to protect them.
• Reliance in part on trade secrets to protect technology, with failure to obtain or maintain protection limiting competitive ability.
• Macroeconomic trends, including rising inflation, interest rate hikes, and uncertainty in international trade relations, could negatively affect business growth and results of operations.

Future Outlook

The company estimates its current cash and cash equivalents are insufficient to fund operations for the next twelve months, necessitating additional capital through equity offerings, debt financing, or restructuring. It plans to continue efforts to regain Nasdaq compliance by December 31, 2025, by meeting the minimum equity standard and phasing down to the Nasdaq Capital Market. Future performance depends on increasing sales of its Vegan Silk Technology Platform, identifying new commercial opportunities, and managing research and development investments effectively.

Management Comments

• "We believe that our future performance and success depends on, to a substantial extent, our ability to capitalize on the following opportunities, which in turn is subject to significant risks and challenges."
• "We believe it is appropriate to use the simplified method in determining the expected life of options because we do not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term for options."
• "Management believes that the ultimate resolution of any such matters [litigation] will not have a material adverse effect on the financial position or results of operations of the Company."
• "Management has represented that the Company was in compliance with all applicable covenants under the Amended Senior Note."
• "The Company is undertaking measures to regain compliance within the extension period, however, there can be no assurance that the Company will ultimately regain compliance with the Equity Rule or be able to maintain compliance with all other applicable requirements for continued listing on the Nasdaq."
• "The Company's executive officers and directors have studied and fully understand the nature of the transaction contemplated by this Agreement and recognize that they have a potential dilutive effect. The board of directors of the Company has concluded in its good faith business judgment that such transaction is in the best interests of the Company."

Industry Context

The company operates in the biomaterials industry, specifically focusing on vegan protein polymers (b-silk and xl-silk) as a substitute for silicone elastomers in beauty and personal care. This positions it within the growing market for sustainable and ethical ingredients, competing against established silicone products and other new biomaterial entrants. The discontinuation of Mylo (leather alternative) indicates a strategic focus on the beauty and personal care segment. The reliance on a single manufacturing partner and limited customer base suggests a niche or early-stage market position within the broader biomaterials landscape.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to global benchmarks. It mentions facing "substantial competition from incumbent materials as well as other new entrants."
• The company's product, Vegan Silk Technology Platform, aims to replace silicone elastomers, indicating a competitive stance against established chemical-based ingredients in the beauty and personal care market.
• The company's financial performance, characterized by historical losses and going concern doubt, is typical of early-stage biomaterials companies that require significant R&D investment and face challenges in scaling production and market adoption.

Management Changes

Corporate Governance

Legal Proceedings

• Donoghue v. Golden Arrow Sponsor, LLC: A lawsuit filed on June 29, 2025, in the U.S. District Court for the Southern District of New York, naming the company as a nominal defendant. Claims were asserted under Section 16(b) of the Securities Exchange Act of 1934 against Golden Arrow Sponsor, LLC. The company was not accused of wrongdoing. The plaintiff filed a notice of dismissal on November 5, 2025, and the case was terminated on November 6, 2025.

Related Party Transactions

• Private Placement Warrants: Warrants to purchase common stock issued to Golden Arrow Sponsor, LLC (the Sponsor). These were exchanged for new Sponsor Warrants on February 14, 2025, with an exercise price of $10.00 per share.
• Sponsor Settlement Agreement: Entered into on February 14, 2025, with Golden Arrow Sponsor, LLC, regarding excise tax liability and potential financing. The company received a $0.4 million settlement payment from the Sponsor in August 2025.
• Technical Development Agreements (2021 TDA, 2022 TDA): Agreements with Ginkgo Bioworks, Inc. (Ginkgo) for technical services. Ginkgo also held Senior Secured Notes and a Convertible Note from the company.
• Amended Senior Note: A modified debt instrument with Ginkgo Bioworks, Inc., with a principal balance of $11.8 million and an effective interest rate of 8.3%. Interest payments were deferred via waiver agreements in July and August 2025.

Stakeholder Impact

• Shareholders: Potential for significant dilution from ongoing and future equity raises (Triton, August PIPE, Ascent ELOC, Seneca Transaction). Risk of delisting from Nasdaq could negatively impact share price and liquidity. A 1-for-20 reverse stock split already occurred.
• Employees: Stock-based compensation is a significant component of expenses. Increased personnel costs in R&D and G&A, excluding stock-based compensation, indicate some growth in headcount.
• Customers: Increased sales of Vegan Silk Technology Platform products, including new partnerships (Goddess Maintenance Company) and reorders, indicate positive product reception. However, high customer concentration poses a risk if major customers are lost.
• Creditors: The company has long-term debt (Amended Senior Note) and excise tax payable. Interest payment deferrals and debt extinguishment transactions (Seneca) impact creditor relationships.
• Suppliers: The Seneca Transaction involved settling $1.7 million of vendor payables by issuing common stock, impacting suppliers who were owed money. Reliance on a single manufacturing partner (Laurus Bio) creates a concentration risk.

Next Steps

• Fund operating, investing, and financing cash flow needs for the next twelve months through public or private equity offerings, debt financing, or debt restructuring.
• Continue efforts to regain compliance with Nasdaq listing standards by December 31, 2025, specifically the minimum equity standard, and phase down to the Nasdaq Capital Market.
• Remediate identified material weaknesses in internal control over financial reporting, including hiring key finance roles, engaging consultants, and implementing formal policies and IT general controls.
• Increase sales of Vegan Silk Technology Platform products to existing and new customers.
• Continue investments in research and development for product opportunities.
• Make estimated monthly payments of $0.04 million to the IRS for the $2.925 million excise tax liability.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by the "substantial doubt" about its ability to continue as a going concern, a large accumulated deficit, and negative working capital. While revenue growth and reduced operating losses are positive, they are insufficient to overcome the fundamental liquidity issues. The ongoing Nasdaq delisting threat, despite an extension, adds significant uncertainty and risk to shareholder value. Continuous reliance on dilutive capital raises to sustain operations, coupled with identified material weaknesses in internal controls, suggests a high-risk investment profile. A seasoned investor would likely view the company's long-term viability as highly questionable and recommend selling to mitigate further losses.

Keywords

Biomaterials, Vegan Silk Technology, b-silk, xl-silk, Beauty and Personal Care, Silicone Elastomer Substitute, SEC Filing, 10-Q, Nasdaq Listing, Going Concern, Capital Raise, Financial Performance, Biomanufacturing, Corporate Governance, Risk Management